StreetInsider.com News Articles

KidneyIntelX® Delivers Unprecedented Two-Year Real-World Outcomes in Diabetic Kidney Disease: No Comparable Risk Assessment Tool Exists

Tue, 30 Jun 2026 07:43:00 -0400

Landmark study of 2,470 patients across two U.S. health systems demonstrates sustained risk-stratified improvements in kidney function, increases in guideline-directed therapy uptake, and - for the first time - measurable reduction in individual patient risk trajectories over 24 months

NEW YORK, June 30, 2026 /PRNewswire/ -- Renalytix PLC (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, today announced results published in the peer-reviewed medical journal Diabetes, Obesity and Metabolism from its most comprehensive real-world evidence (RWE) study to date for its FDA-approved kidneyintelX.dkd test.

KidneyIntelX® Delivers Unprecedented Two-Year Real-World Outcomes in Diabetic Kidney Disease: No Comparable Risk Assessment Tool Exists

Tue, 30 Jun 2026 07:43:00 -0400

KidneyIntelX® Delivers Unprecedented Two-Year Real-World Outcomes in Diabetic Kidney Disease: No Comparable Risk Assessment Tool Exists

Tue, 30 Jun 2026 07:43:00 -0400

KidneyIntelX® Delivers Unprecedented Two-Year Real-World Outcomes in Diabetic Kidney Disease: No Comparable Risk Assessment Tool Exists

Tue, 30 Jun 2026 07:43:00 -0400

KidneyIntelX® Delivers Unprecedented Two-Year Real-World Outcomes in Diabetic Kidney Disease: No Comparable Risk Assessment Tool Exists

Tue, 30 Jun 2026 07:43:00 -0400

KidneyIntelX® Delivers Unprecedented Two-Year Real-World Outcomes in Diabetic Kidney Disease: No Comparable Risk Assessment Tool Exists

Tue, 30 Jun 2026 07:43:00 -0400

KidneyIntelX® Delivers Unprecedented Two-Year Real-World Outcomes in Diabetic Kidney Disease: No Comparable Risk Assessment Tool Exists

Tue, 30 Jun 2026 07:43:00 -0400

KidneyIntelX® Delivers Unprecedented Two-Year Real-World Outcomes in Diabetic Kidney Disease: No Comparable Risk Assessment Tool Exists

Tue, 30 Jun 2026 07:43:00 -0400

KidneyIntelX® Delivers Unprecedented Two-Year Real-World Outcomes in Diabetic Kidney Disease: No Comparable Risk Assessment Tool Exists

Tue, 30 Jun 2026 07:43:00 -0400

KidneyIntelX® Delivers Unprecedented Two-Year Real-World Outcomes in Diabetic Kidney Disease: No Comparable Risk Assessment Tool Exists

Tue, 30 Jun 2026 07:43:00 -0400

KidneyIntelX® Delivers Unprecedented Two-Year Real-World Outcomes in Diabetic Kidney Disease: No Comparable Risk Assessment Tool Exists

Tue, 30 Jun 2026 07:43:00 -0400

KidneyIntelX® Delivers Unprecedented Two-Year Real-World Outcomes in Diabetic Kidney Disease: No Comparable Risk Assessment Tool Exists

Tue, 30 Jun 2026 07:43:00 -0400

Renalytix™ and Carna Health Partner to Solve Kidney Disease Crisis: Bridging the Existing Gap Between Population Screening and Precision Intervention

Tue, 12 May 2026 07:43:00 -0400

The novel care model will integrate FDA-approved kidneyintelX.dkd™ and Carna Health's digital health platform to identify at-risk patients, halt disease progression, and slash healthcare costs, significantly benefiting US health systems and providers

NEW YORK and BOSTON, May 12, 2026 /PRNewswire/ -- Renalytix PLC (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, and Carna Health, an AI-enabled digital health company revolutionizing chronic disease prevention, both leaders in improving outcomes in chronic kidney disease (CKD), today announced a landmark partnership designed to transform how health systems identify, stratify, and manage chronic kidney disease and its

Renalytix™ and Carna Health Partner to Solve Kidney Disease Crisis: Bridging the Existing Gap Between Population Screening and Precision Intervention

Tue, 12 May 2026 07:43:00 -0400

Renalytix™ and Carna Health Partner to Solve Kidney Disease Crisis: Bridging the Existing Gap Between Population Screening and Precision Intervention

Tue, 12 May 2026 07:43:00 -0400

Renalytix™ and Carna Health Partner to Solve Kidney Disease Crisis: Bridging the Existing Gap Between Population Screening and Precision Intervention

Tue, 12 May 2026 07:43:00 -0400

Renalytix™ and Carna Health Partner to Solve Kidney Disease Crisis: Bridging the Existing Gap Between Population Screening and Precision Intervention

Tue, 12 May 2026 07:43:00 -0400

Renalytix™ and Carna Health Partner to Solve Kidney Disease Crisis: Bridging the Existing Gap Between Population Screening and Precision Intervention

Tue, 12 May 2026 07:43:00 -0400

Renalytix™ and Carna Health Partner to Solve Kidney Disease Crisis: Bridging the Existing Gap Between Population Screening and Precision Intervention

Tue, 12 May 2026 07:43:00 -0400

Renalytix™ and Carna Health Partner to Solve Kidney Disease Crisis: Bridging the Existing Gap Between Population Screening and Precision Intervention

Tue, 12 May 2026 07:43:00 -0400

Form SCHEDULE 13D/A Renalytix plc Filed by: JEFFERSON RIVER CAPITAL LLC

Mon, 23 Feb 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260223/26043668.html

Form SCHEDULE 13D/A Renalytix plc Filed by: JEFFERSON RIVER CAPITAL LLC

Mon, 23 Feb 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260223/26043668.html

Form SCHEDULE 13D/A Renalytix plc Filed by: JEFFERSON RIVER CAPITAL LLC

Mon, 23 Feb 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260223/26043668.html

Form F-6 POS Renalytix plc Filed by: Citibank,N.A./ADR

Wed, 03 Dec 2025 16:07:00 -0400

si-local-file:///var/storage/secattach/20251203/25695474.html

Form F-6 POS Renalytix plc Filed by: Citibank,N.A./ADR

Wed, 03 Dec 2025 16:07:00 -0400

si-local-file:///var/storage/secattach/20251203/25695474.html